Related Experiment Videos
Cefmenoxime kinetics during continuous ambulatory peritoneal dialysis.
European Journal of Clinical Pharmacology
|January 1, 1986
Summary
Cefmenoxime pharmacokinetics in patients on peritoneal dialysis show minimal drug loss. Standard doses for renal failure can be used for systemic infections in these patients.
Area of Science:
- Pharmacology
- Nephrology
- Infectious Diseases
Background:
- Continuous ambulatory peritoneal dialysis (CAPD) alters drug pharmacokinetics.
- Understanding cefmenoxime elimination in CAPD patients is crucial for effective dosing.
Purpose of the Study:
- To determine the pharmacokinetic profile of cefmenoxime in adult subjects undergoing CAPD.
- To assess cefmenoxime elimination via renal and peritoneal clearance.
Main Methods:
- Intravenous infusion of cefmenoxime (15 mg/kg) over 30 minutes in 6 CAPD subjects.
- Serum, urine, and dialysate concentrations measured using high-pressure liquid chromatography.
- Pharmacokinetic parameters calculated, including elimination half-life and clearance.
Main Results:
- Mean peak serum concentration: 92.8 ± 11.6 µg/ml.
- Elimination half-life: 5.46 hours.
- Total body clearance: 31 ± 7.7 ml/min.
- Renal and peritoneal elimination accounted for 8% and 5.75% of the dose, respectively.
- Peritoneal clearance was 1.93 ± 68 ml/min.
Conclusions:
- Peritoneal losses of cefmenoxime are minimal during CAPD.
- Conventional doses used in advanced renal failure are likely suitable for treating systemic infections in CAPD patients.